For the quarter ending 2025-09-30, RAPP had $196,292K increase in cash & cash equivalents over the period. -$17,599K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -26,925 | -50,795 |
| Depreciation and amortization | 256 | 496 |
| Net (accretion) and amortization of investments in marketable securities | -204 | 528 |
| Non-cash lease expense | 567 | 894 |
| Stock-based compensation expense | 4,735 | 8,429 |
| Prepaid expenses and other current assets | -2,534 | 5,144 |
| Other assets | 362 | 548 |
| Accounts payable | -179 | 1,216 |
| Accrued expenses and other current liabilities | 1,696 | 784 |
| Operating lease liabilities | -9 | 111 |
| Net cash used in operating activities | -17,465 | -45,307 |
| Purchases of short-term investments | 101,620 | 56,093 |
| Maturities of short-term investments | 44,978 | 100,033 |
| Purchases of property and equipment | 134 | 313 |
| Net cash used in investing activities | -56,776 | 43,627 |
| Proceeds from underwritten public offering, net of underwriter discounts and commissions and deferred offering costs | 269,834 | - |
| Proceeds from exercise of stock options | 636 | 6 |
| Payment of deferred offering costs | - | 63 |
| Repurchase of unvested restricted common stock | 0 | 1 |
| Net cash provided by financing activities | 270,533 | -58 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | 196,292 | -1,738 |
| Cash and cash equivalents at beginning of period | 56,910 | - |
| Cash and cash equivalents at end of period | 251,464 | - |
Rapport Therapeutics, Inc. (RAPP)
Rapport Therapeutics, Inc. (RAPP)